ArticleCancers2025
Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWhile there have been limited reports suggesting a possible association between Monoclonal Gammopathy (MG) of Undetermined Significance (MGUS) and prostate cancer, a clear biological correlation has yet to be established.
methodsIn this study, we aimed to investigate the incidence of MGUS in a cohort of 168 patients undergoing TRUSBx for suspected prostate cancer between September 2022 and December 2023.
resultsOur findings revealed that the incidence of MGUS, identified by serum immunofixation or abnormal free light chain ratio, was significantly higher in this cohort than the anticipated global incidence (33.93% vs. 5%). Furthermore, the prevalence of MGUS was higher in patients with a Gleason Score (GS) exceeding 7 compared to those with GS6 or with ASAP/HG PIN (34.2% vs. 28% vs. 25%, respectively). A systematic univariate analysis of 42 clinical and biological variables identified fibrinogen levels, neutrophil-to-lymphocyte ratio, and the percentage of alpha2 band in serum protein electrophoresis as significantly associated with MGUS presence.
conclusionsThese findings suggest that a systemic inflammatory status and a highest GS in these patients may increase the likelihood of detecting an MGUS. To our knowledge, this study is the first to suggest an association between prostate cancer and MG. Further and larger studies are required to confirm the increased prevalence of MGUS within this target population and to establish the clinical relevance of these precocious diagnoses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.